The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase inhibitors therapy impairs vaccine-induced imm...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jonathan A Cook, Piers Patten, Nicholas Peckham, Paul Moss, Abhishek Abhishek, Vicki S Barber, Anne Francis, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Gratian Vandici, Gareth Plested, Lucy Eldridge, Patrick Julier, Thomas Roberts, Marie Hodges, Helen M Parry
Format:	Artigo
Idioma:	Inglês
Publicat:	NIHR Journals Library 2025-11-01
Col·lecció:	Efficacy and Mechanism Evaluation
Matèries:	immunity chronic lymphocytic leukaemia antibody vaccination immunocompromised bruton tyrosine kinase inhibitor covid-19
Accés en línia:	https://doi.org/10.3310/AJED1124
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!